# Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C

Study · id `cardio:ct-nct03531905` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03531905](<https://clinicaltrials.gov/study/NCT03531905>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03531905

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 242 participants.

## Technical summary

Registry record NCT03531905. Randomized; triple masking; primary purpose treatment. Start 2018-05-09 (actual); primary completion 2019-06-18 (actual). Results posted on 2020-04-09.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 242 participants (enrolled count; ClinicalTrials.gov record NCT03531905, source copy `cardio:ctgov-nct03531905-2020-04-09`, retrieved 2026-10-26)
- Started: 2018-05-09 (actual) (ClinicalTrials.gov record NCT03531905, source copy `cardio:ctgov-nct03531905-2020-04-09`, retrieved 2026-10-26)
- Primary completion: 2019-06-18 (actual) (ClinicalTrials.gov record NCT03531905, source copy `cardio:ctgov-nct03531905-2020-04-09`, retrieved 2026-10-26)
- Completion: 2019-06-18 (actual) (ClinicalTrials.gov record NCT03531905, source copy `cardio:ctgov-nct03531905-2020-04-09`, retrieved 2026-10-26)
- Results first posted: 2020-04-09 (ClinicalTrials.gov record NCT03531905, source copy `cardio:ctgov-nct03531905-2020-04-09`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03531905, source copy `cardio:ctgov-nct03531905-2020-04-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03531905-2020-04-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Condition: Cholesterolemia
- Intervention (Drug): Bempedoic acid + Ezetimibe FDC Oral Tablet
- Intervention (Drug): Ezetimibe 10 mg Oral Tablet
- Intervention (Drug): Placebo Oral Tablet
- Intervention (Drug): Placebo oral capsule
- Lead sponsor: Esperion Therapeutics, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Esperion Therapeutics, Inc. (`cardio:org-esperion-therapeutics-inc`)

## Provenance

Content hash: 79aff5ece583e255b3386b206bdac849e188c90766c92d499c04bbf29c4b66d6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
